Huiyu Pharmaceutical(SH:688553) Xin Lang Cai Jing·2025-10-23 03:09Core Points - On October 23, Huayu Pharmaceutical experienced a decline of 5.02%, trading at 20.83 CNY per share, with a transaction volume of 75.7042 million CNY and a turnover rate of 1.04%, resulting in a total market capitalization of 8.824 billion CNY [1] - Huayu Pharmaceutical, established on October 12, 2010, and listed on October 26, 2021, focuses on the research, production, and domestic and international sales of oncology drugs and complex injectable drugs [1] - The company's revenue composition is primarily from drug sales (97.27%), followed by technical services (1.66%) and other sources (1.07%) [1] Fund Holdings - According to data, Yongying Fund holds a significant position in Huayu Pharmaceutical through its fund Yongying Medical Health A (008618), which held 219,600 shares in the second quarter, accounting for 3.56% of the fund's net value, ranking as the tenth largest holding [2] - The fund, established on May 20, 2020, has a latest scale of 24.1775 million CNY, with a year-to-date return of 14.74% and a one-year return of 12.38%, ranking 3177 out of 4218 and 2997 out of 3875 in its category, respectively [2] - The fund manager, Shan Lin, has been in the position for 1 year and 125 days, overseeing total assets of 3.143 billion CNY, with the best fund return during his tenure being 103.91% and the worst being 13.89% [2]